The role of CaMKII in regulation of cardiac function in heart fai | 54318
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

+44 1300 500008

The role of CaMKII in regulation of cardiac function in heart failure

Global Summit on Heart Diseases and Therapeutics

October 20-21, 2016 Chicago, USA

Yanggan Wang

Wuhan University, China

Scientific Tracks Abstracts: J Clin Exp Cardiolog

Abstract :

Objective: The excessive activation of calmodulin-dependent protein kinase II (CaMKII) plays a key role in heart failure (HF) development. As a result, CaMKII becomes a novel therapeutic target. Here, we studied alterations of systolic and diastolic function; �?²-adrenergic regulation and exercise tolerance in pressure overload HF mice after acute and 1 week chronic CaMKII inhibition. Methods & Results: Pressure overload HF was induced by severe thoracic aortic banding (sTAB), while cardiac function was monitored by M-mode echocardiography. CaMKII inhibitor KN93 was given intraperitoneally to HF mice for one time (acute inhibition) and once a day for continuous 7 days (chronic inhibition), respectively. Acute and chronic CaMKII inhibition improved systolic function but the diastolic function was reduced, especially for the chronic inhibition, manifested by the increase in E/Em ratio and site of left atrium. We have tested the effects of CaMKII inhibition on adrenergic stimulation in HF mice by isoproterenol (ISO) injection or 10 min swimming before and after acute and chronic CaMKII inhibition, we found that chronic CaMKII inhibition significantly enhanced the positive inotropic effect of ISO or swimming with a recovery of �?²1-AR expression illustrated by Western blots. An interesting finding was that after acute CaMKII inhibition, the HF mice started sinking in water in several seconds of swimming. Conclusion: Chronic inhibition of CaMKII improved systolic function, adrenergic regulation and exercise tolerance in HF mice. The diastolic function is impaired, which is more prominent for acute CaMKII inhibition.

Biography :

Yanggan Wang is a Professor and the Director of Department of Cardiology, Zhongnan Hospital of Wuhan University, China. He has completed his MD and PhD from Tongji Medical University, China and Post-doctoral training from Germany Heart Center of Technical University of Munich, Germany and Emory University, USA. He has published 40 peer-reviewed papers in highly impacted journals and has been serving as an Editorial Board Member of 3 prestigious medical journals. He has been awarded NIH R01 and R21 grants in USA; and the General Project Award and the Key Project Award from the National Natural Science Foundation in China.